BofA Securities analyst Alec Stranahan maintains $Perspective Therapeutics (CATX.US)$ with a hold rating, and maintains the target price at $6.
According to TipRanks data, the analyst has a success rate of 51.2% and a total average return of -2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Perspective Therapeutics (CATX.US)$'s main analysts recently are as follows:
Perspective Therapeutics recently presented data for VMT-alpha-NET, which did not meet the expected overall response rate (ORR) when compared to industry benchmarks. There remains an opportunity for Perspective to achieve improved responses with higher dosage levels, though further data is not anticipated until late-2025 pending regulatory advancements. Additionally, initial findings for VMT01 in melanoma indicated kidney accumulation issues that could restrict dose escalation, potentially impacting the stock until further combination studies provide additional data.
Initial data from Cohort 1 and Cohort 2 of VMT-a-NET's phase I/IIa study indicate encouraging signals but underscore the need for patience in dose optimization. There appears to be a path to potential commercialization from Perspective's leading specific chelator across its pipeline and platform.
Yesterday's selloff in Perspective Therapeutics was seen as an overreaction to the early data from the dose escalation phase of the VMT-alpha-NET program, which showed clinical activity correlating with dose intensity and a clear safety profile that supports further dose escalation. This situation presents a buying opportunity, particularly with Perspective trading near cash levels.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美银证券分析师Alec Stranahan维持$Perspective Therapeutics (CATX.US)$持有评级，维持目标价6美元。
根据TipRanks数据显示，该分析师近一年总胜率为51.2%，总平均回报率为-2.7%。
此外，综合报道，$Perspective Therapeutics (CATX.US)$近期主要分析师观点如下：
Perspective Therapeutics最近公布了VMT-Alpha-Net的数据，与行业基准相比，该数据未达到预期的总体响应率（ORR）。Perspective仍有机会通过更高的剂量水平改善反应，尽管预计要到2025年底才能获得更多数据，等待监管方面的进展。此外，黑色素瘤中 VMT01 的初步发现表明存在肾脏积累问题，这可能会限制剂量增加，在进一步的组合研究提供更多数据之前，可能会对种群产生影响。
来自VMT-a-Net的I/IIa期研究队列1和队列2的初步数据显示出令人鼓舞的信号，但突显了在剂量优化方面需要耐心。Perspective领先的特定螯合剂在其产品线和平台上似乎有一条潜在的商业化之路。
Perspective Therapeutics昨天的抛售被视为对VMT-Alpha-Net计划剂量递增阶段的早期数据的过度反应，该数据显示临床活动与剂量强度相关，并且有明确的安全特征支持剂量进一步增加。这种情况提供了买入机会，尤其是在Perspective交易接近现金水平的情况下。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
